Intranasal influenza-vectored COVID-19 vaccine restrains the SARS-CoV-2 inflammatory response in hamsters

Abstract

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants and “anatomical escape” characteristics threaten the effectiveness of current coronavirus disease 2019 (COVID-19) vaccines. There is an urgent need to understand the immunological mechanism of broad-spectrum respiratory tract protection to guide broader vaccines development. Here we investigate immune responses induced by an NS1-deleted influenza virus vectored intranasal COVID-19 vaccine (dNS1-RBD) which provides broad-spectrum protection against SARS-CoV-2 variants in hamsters. Intranasal delivery of dNS1-RBD induces innate immunity, trained immunity and tissue-resident memory T cells covering the upper and lower respiratory tract. It restrains the inflammatory response by suppressing early phase viral load post SARS-CoV-2 challenge and attenuating pro-inflammatory cytokine (Il6, Il1b, and Ifng) levels, thereby reducing excess immune-induced tissue injury compared with the control group. By inducing local cellular immunity and trained immunity, intranasal delivery of NS1-deleted influenza virus vectored vaccine represents a broad-spectrum COVID-19 vaccine strategy to reduce disease burden.

Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study

“…In animal models, dNS1-RBD also inhibits the inflammatory response by suppressing early phase viral load post SARS-CoV-2 infection and attenuating pro-inflammatory cytokine levels ( Il6, Il1b, and Ifng ), which reduces the immune-induced tissue injury. 22 Further investigation of the underlying protection mechanism is needed.…”

From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019

“…Subsequent human trials established that the vaccine had a good safety profile, with an overall incidence of adverse reactions of only 19% 106 . It is the world's first IN vaccine to enter Phase III clinical trials and has already been approved for use in China in December 2022 under the name Pneucolin 107 …”

“… 106 It is the world's first IN vaccine to enter Phase III clinical trials and has already been approved for use in China in December 2022 under the name Pneucolin. 107 …”

Intranasal Route: A Nasocerebral Approach against SARS-CoV-2 in NeuroCOVID

“…The objective of the use of the intranasal route in COVID-19 and long-COVID could be for (a) prophylaxis or (b) treatment of neuroCOVID in these groups of patients. For COVID-19 the trend to use COVID-19 intranasal vaccine has emerged recently and reviewed , with variable success rates. The use of drugs targeting SARS-CoV-2 has been tested in animal models with success.…”